FGFR2b Logo

FGFR2b is an emerging, potentially prognostic protein biomarker in advanced gastric/GEJ cancers1,2

Overexpression of FGFR2b protein drives tumorigenesis3,4

Graph illustrating the rising number of prostate cancer patients, highlighting a concerning trend in cancer prevalence

FGFR2b protein overexpression may be prognostic and associated with shorter survival in gastric/GEJ cancers2

FGFR2b protein overexpression is defined as 2+/3+ membrane staining intensity, as detected via immunohistochemistry (IHC] tissue-based testing2,5,6

Prevalance of FGFR2b protein overexpression in patients with gastric/GEJ cancers1

chart-pie chart-pie

FGFR2b protein overexpression is distinct from FGFR2 gene amplification 1,7-9

Gastric/GEJ cancer detected by IHC | Cholangiocarcinoma detected by NGS or PCR | Urothelial cancer detected by NGS or PCR
gene-amplification-mob
  • FGFR2b protein overexpression can occur in the absence of FGFR2 gene amplification where it is reported to occur in 2%–9% of gastric cancers, measured by NGS/PCR5,8,9,11-13

FGFR2b protein: a biologically distinct splice isoform that influences cell behavior14

Diagram of FGFR2 gene splicing into FGFR2b and FGFR2c protein isoforms in epithelial and mesenchymal cells
fgfr2-family-mob
SEE HOW IHC STAINING CAN DETECT FGFR2b

FGF, fibroblast growth factor; FGFR2, fibroblast growth factor receptor 2; FGFR2b, fibroblast growth factor receptor 2, isoform IIIb; FGFR2c, fibroblast growth factor receptor 2, isoform IIIc; GEJ, gastroesophageal junction; NGS, next-generation sequencing; PCR, polymerase chain reaction.

References: 1. Rha SY, et al. JCO Precis Oncol. 2025;9:e2400710. 2. Ahn S, et al. Mod Pathol. 2016;29:1095-1103. 3. Turner N, et al. Nat Rev Cancer. 2010;10:116-129. 4. Khosravi F, et al. Front Cell Dev Biol. 2021;9:672935. 5. Wainberg ZA, et al. Lancet Oncol. 2022;23:1430-1440. 
6. Wainberg ZA, et al. Gastric Cancer. 2024;27:558–570. 7. Sato Y, et al. J Clin Med. 2023;12:4646. 8. Han N, et al. Pathobiology. 2015;82:269-279. 9. Zhang J, et al. Cells. 2019;8:637. 10. Krook MA, et al. Br J Cancer. 2021;124:880-892. 11. Catenacci DVT, et al. J Clin Oncol. 2020;38:2418-2426. 12. De Luca A, et al. Int J Mol Sci. 2020;21:6856. 13. Li L, et al. J Gastrointest Oncol. 2022;13:77-83. 14. Warzecha CC, et al. Molecular Cell. 2009;33:591-601.15. Chioni AM, et al. Cancers. 2021;13:5681. 16. Jimenez-Pascual A, et al. Cells. 2019;8:715.

References: 1. FPO 2. FPO 3. FPO